› 4kjy

X-ray diffraction
1.93Å resolution

Complex of high-affinity SIRP alpha variant FD6 with CD47

Released:
DOI: 10.2210/pdb4kjy/pdb
PDB entry 4kjy coloured by chain, front view.
PDB entry 4kjy coloured by chain, side view.
PDB entry 4kjy coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC
Science 341 88-91 (2013)
PMID: 23722425

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-552979 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Leukocyte surface antigen CD47 Chains: A, C
Molecule details ›
Chains: A, C
Length: 125 amino acids
Theoretical weight: 14.25 KDa
Source organism: Homo sapiens
Expression system: Trichoplusia ni
High-affinity SIRPa variant FD6 Chains: B, D
Molecule details ›
Chains: B, D
Length: 133 amino acids
Theoretical weight: 14.52 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21(DE3)

Ligands and Environments

2 bound ligands:
Ligand SO4 3 x SO4
Ligand NAG 8 x NAG
1 modified residue:
Ligand PCA 2 x PCA

Experiments and Validation Details

Entry percentile scores
X-ray source: ALS BEAMLINE 8.2.1
Spacegroup: P6522
Unit cell:
a: 71.34Å b: 71.34Å c: 399.18Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.221 0.219 0.262
Expression systems:
  • Trichoplusia ni
  • Escherichia coli BL21(DE3)

Quick links

Citations

119 review citations

Tumour-associated macrophages as treatment targets in oncology.
Mantovani et al. (2017)
118 more

3 mentions without citation

Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function.
Jalil et al. (2020)
2 more